The April 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from injectable fillers, botulinum toxin in hidradenitis suppurativa, cannabis and cannabinoid product use, to psoriasis, melasma, onychomycosis and everything in between, we share this month’s issue highlights straight from the JDD Editor’s desk:
An understanding of anatomy optimizes results and decreases complications in Anatomical Considerations for Injectable Fillers in the Face: How to Reduce Complications and Optimize Aesthetic Results.
Despite the emergence of multiple biologic drug options for psoriasis, unmet treatment needs remain in Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics.
Current Issues in Global Onychomycosis Management confirms that similar strategies are used across surveyed regions and that more diagnostic and pharmaceutical options are needed to improve onychomycosis outcomes.
The combination of LYT2 and LVS was well-tolerated and improved the appearance of hyperpigmentation and overall quality in Assessment of Circadian-based Antioxidants Plus a Comprehensive Brightener in Skin of Color Patients With Hyperpigmentation.
The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast assesses the effect of twice-weekly maintenance doses of Cal/BD foam after 4 weeks of standard once-daily treatment in combination with apremilast.
Expert Recommendations on the Use of Hyaluronic Acid Filler for Tear Trough Rejuvenation are discussed and agreed as a consensus, according to cross-sectional expertise and clinical experience.
Oral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen demonstrates the effectiveness and safety profile of utilizing oral TXA to treat recalcitrant melasma and highlights a possible dosing regimen that can be used for the novel therapy.
Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study compares treatment patterns of IXE-treated and ADA-treated patients with psoriasis over 24 months in the United States.
Botulinum toxin is a safe and potentially effective alternative for hidradenitis suppurativa patients resistant to standard of care therapies in Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review.
Data to date supports the potential for targeting the cutaneous endocannabinoid system to treat eczematous dermatoses in Evaluation of Cannabis and Cannabinoid Product Use, Knowledge, and Attitudes in the Eczema Community.
The adjuvant property of vaccines offers a plausible mechanism by which vaccines could induce AA in A Case of Late-Onset Alopecia Areata.
Early recognition of SS and its associations with medications has potential to significantly improve patient morbidity and mortality in Deep Sweet Syndrome Secondary to Pegfilgrastim.
Improvement of Unilateral Breast Hypoplasia With Oral Spironolactone in a Patient With Becker Nevus Syndrome supports consideration of oral spironolactone in the treatment of BN-associated breast hypoplasia.
Prospective studies are warranted to better characterize risk/benefit profile in Pustular and Erythrodermic Psoriasis in Patients Treated With Oral Glucocorticoids: A Survey of United States Dermatologists.
A prospective split body was conducted to assess Safety and Efficacy of Intense Pulsed Light With Radiofrequency in United States Hidradenitis Suppurativa Patients.
Physicians should educate their patients on dietary supplements to avoid drug-supplement interactions and address the factors that influence the use of over-the-counter skin supplements in Demographics of Dietary Supplement Use for Skin: An Analysis of NHANES Cross-Sectional Data.
Research is warranted to delineate therapeutic regimens that address the clinical spectrum of disease in A Retrospective Study of Idiopathic Granulomatous Mastitis Treatment and Outcomes.
An Analysis of Skin of Color Publications in the Journal of Drugs in Dermatology from 2018 to 2020 was conducted using a novel classification system.
Find more JDD Issue Highlights here.
